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Coronary heart disease (CHD) is a major public health concern, affecting almost 16 million 
people in the U.S. and leading to 452,300 deaths in 2004 alone. Low levels of high density 
lipoprotein (HDL) cholesterol have been shown to increase the risk for cardiovascular disease 
(CVD). The role of genetics in affecting total cholesterol, HDL-cholesterol, and triglycerides 
levels is significant, with heritability estimates exceeding 50%. Recent studies have identified 
major loci associated with HDL-cholesterol through genome-wide association studies, which 
investigated influences of common variants on common traits. Relatively few studies have 
investigated the impact of rare variants on common disease. The aim of our study was to 
evaluate the role of genetic variation in APOA2 (a biological candidate gene involved in HDL 
metabolism) in relation to HDL-cholesterol levels in epidemiological samples of African Blacks 
and U.S. Non-Hispanic Whites (NHWs). We resequenced the entire APOA2 gene in individuals 
with HDL-cholesterol levels in the upper 5th percentile (47 NHWs and 48 Blacks) and lower 5th 
percentile (48 NHWs and 47 Blacks), allowing us to identify both rare and common variants. 
Common tagSNPs and all rare variants were screened in the larger NHW and Black samples for 
associations with HDL-cholesterol levels. We detected a total of 26 variants (25 single 
nucleotide substitutions and 1 microsatellite); 12 of which were previously unreported. Of the 12 
new variants, 6 were present in NHWs and 6 in Blacks. We observed an increased number of 
minor alleles of APOA2 variants (either increased heterozygosity for rare variants or increased 
homozygosity for common variants) in subjects with low HDL levels that was more pronounced 
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in NHWs. We performed a preliminary analysis using a total of 9 variants that were screened in 
NHWs (n=624, 8 variants) and Blacks (n=788, 5 variants) with TaqMan SNP genotyping assays 
to date. For the 8 variants that were screened in NHWs, we found significant association in only 
females for variants 2233C>T/rs6413453 (p=0.028) and 3251A>G (p=0.023). Completing 
genotyping for remaining variants will allow us to determine the extent to which APOA2 variants 
influence HDL levels.  
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 HEART DISEASE AND CHOLESTEROL LEVELS 
Almost 16 million people in the U.S. are living with coronary heart disease (CHD), 
leading to 452,300 deaths in 2004 alone (Rosamond et al., 2007). The estimated direct and 
indirect cost of cardiovascular disease (CVD) in the U.S. for 2007 was $431.8 billion (Rosamond 
et al., 2007). Many factors influence the risk to develop heart disease including environmental 
factors like physical activity and diet and genetic factors like genes influencing lipid metabolism. 
Combining data from two twin studies, Berg et al. (1987) found that almost 50% of the variation 
of the lipid profile is under genetic control. Because of the significant contribution of genetics to 
CHD, understanding the underlying genetic influence of this disease is vital.  
Risk factors for CHD include cigarette smoking, abnormal blood lipid levels, 
hypertension, diabetes, abdominal obesity, a lack of physical activity, low daily fruit and 
vegetable consumption, alcohol over-consumption, and psychosocial index (Yusuf et al., 2004). 
Hypertension is a particularly powerful risk factor for CHD in black persons, especially in black 
women (Rosamond et al., 2007).  
Cholesterol levels are particularly important because both low levels of high-density 
lipoprotein (HDL) cholesterol and high levels of low-density lipoprotein (LDL) cholesterol have 
been shown to increase the risk for CVD. The American Heart Association website (2008) 
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classifies total cholesterol levels of 240mg/dL as high cholesterol. HDL-cholesterol levels of less 
than 40 mg/dL for men and less than 50 mg/dL for women is considered low HDL-cholesterol, 
which is a major risk factor for heart disease. An LDL-cholesterol level of 160-189 mg/dL is 
considered high, and each person’s target level depends on his/her other risk factors, and could 
be as low as 100 mg/dL or less.  
In 2004, 16.1% of Non-Hispanic White (NHW) males had total cholesterol levels of 240 
mg/dL or higher. The percentage was 14.1% in Non-Hispanic Black (NHB) males, 18.2% in 
NHW females, and 12.5% in NHB (Rosamond et al., 2007). The prevalence of LDL-cholesterol 
levels of 130 mg/dL or higher in NHW males was 31.7%; 32.4% in NHB males; 33.8% in NHW 
females; and 29.8% in NHW females (Rosamond et al., 2007). 
The difference between the sexes is most pronounced in the percentage of individuals 
with HDL-cholesterol levels less than 40 mg/dL. NHW males showed 26.2% in this category; 
15.5% in NHB males. 8.8% in white females, and 6.9% in black females (Rosamond et al., 
2007). 
Clinically, it has been shown that lowering LDL (to under 70 mg/dL) is beneficial for 
individuals who have chronic CHD (Smith et al., 2006). HDL levels also influence CHD risk in 
men and women (Davidson et al., 2007). HDL levels are an independent risk factor for CHD. 
Modifying HDL-cholesterol levels “contributes significantly to both event rate reduction and 
changes in rates of atheromatous plaque progression (Nicholls, 2006; Brown, 2007). 
Many studies have demonstrated the link between HDL levels and CVD. The 
Framingham Heart Study showed that there is an inverse relationship between CVD and HDL 
levels, meaning individuals with the highest HDL levels have the lowest risk for CVD (Castelli 
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et al., 1986). Each 1% increase in HDL-cholesterol was associated with a 2% reduction in the 
development of CHD (Castelli et al., 1986). 
Low HDL levels have been shown to increase the risk of CHD in other studies. In the 
Physician’s Health Study, participants with low HDL had an increased risk for CHD (Stampfer 
et al., 1991). Similar findings were demonstrated in the Israeli Ischemic Heart Disease Study, in 
which subjects with low total cholesterol and high HDL had the lowest rates of CHD-associated 
morbidity and mortality (Goldbourt et al., 1997). Individuals with less than 35 mg/dL HDL-
cholesterol had a 3 times greater risk for CHD as compared to individuals with levels at 35 
mg/dL or higher (Assman et al., 1998). Gordon et al. (1989) found that on average, each 1 mg/dL 
increase in HDL-cholesterol is associated with a 2% decrease in CHD risk in men and a 3% 
decrease in women. 
A number of environmental factors are shown to have a negative affect on HDL-
cholesterol levels (associated with decreased HDL-cholesterol levels), including Body Mass 
Index (BMI) and smoking. Other factors are correlated with increased HDL-cholesterol levels 
including moderate alcohol use, exercise, low sucrose and starch intake, and estrogen. (Women 
have higher HDL-cholesterol levels than men). Any of the many genes involved in HDL 
makeup, production and catabolism could have an affect on CHD as well. 
1.2 GENETICS INFLUENCE ON HEART DISEASE 
Estimates of the proportion of variation that can be attributed to inherited factors 
(heritability estimate) for total cholesterol, HDL-cholesterol, and triglycerides have exceeded 
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50% (Lusis et al., 2004). Researchers have attempted to identify these factors through twin 
studies, family studies and linkage analysis and, most recently, genome-wide association studies. 
Major loci identified associated with HDL-cholesterol at genome-wide significance level 
in two recent studies were ABCA1, the APOA1-APOC3-APOA4-APOA5 gene cluster, CETP, 
LIPC, LIPG, LPL, and GALNT2 (Willer et al., 2008; Kathiresan el al., 2008). By applying 
multiple regression models during their meta-analysis; Willer et al. (2008) found that the variants 
identified in their study accounted for only ~5 to 8% of the variation in the lipid traits in their 
population. Comparing this number to the suggested heritability estimate for HDL-cholesterol, 
we can conclude that additional genetic factors remain to be identified, such as common variants 
with small effects and rare variants with large effects. 
Many candidate genes have been proposed for research in relation to HDL levels in mice 
and in humans (Cambien 2005; Wang et al., 2006; Breslow 1988; Carlson et al. 2004, 
Humphries, 1988). These include biological and position candidate genes in a number of 
different categories, including HDL-associated apoliporoteins, HDL-associated enzymes and 
lipid transfer proteins, enzymes, cell receptors and transporters, and transcription factors such as. 
Since CHD is a complex disease, it is important to investigate each gene and associations of gene 
in their role(s) in contributing to HDL levels and heart disease. 
1.3 HDL METABOLISM  
 The effect of HDL-cholesterol on CHD/CVD could occur by its levels (either by 
increasing synthesis or decreasing catabolism), or by increasing the availability of HDL-
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cholesterol particles without necessarily increasing plasma HDL-cholesterol levels (Robinson et 
al. 2006; Toth et al., 2006).  
The surface of HDL is made up of phospholipids, solubilized cholesterol, enzymes and 
apolipoproteins (Toth et al., 2006). Transcription factors, intracellular signaling pathways, cell 
surface receptors and enzymes all play a role in the regulation of serum HDL levels (Robinson et 
al., 2007; Toth et al., 2006; and Maxfield et al., 2002) 
There are many different hypotheses attempting to explain the atheroprotective role of 
HDL-cholesterol. One hypothesis states that HDL-cholesterol exerts its influence on CHD risk 
through reverse cholesterol transport (Lewis et al., 2005). In reverse cholesterol transport, free 
cholesterol is removed from the peripheral macrophages (in the arterial wall) and is brought to 
the liver by HDL-cholesterol where it is excreted into bile (Toth, 2003). (Refer to Figure 1 for an 
illustration of reverse cholesterol transport.) HDL could reduce atherosclerosis in other ways. For 
example, methionine in apoA-I (carried in HDL’s phospholipids surface), can reduce oxidized 
lipid species in LDL particles, making them anti-atherogenic (Toth, 2003) 
HDL-cholesterol has been shown to perform a number of other functions leading to 
potential alterations of CHD risk including inhibiting expression of endothelial cell adhesion 
molecules, promoting endothelial nitric oxide synthesis and increasing vasodilation, and 
inhibiting pro-thrombotic and pro-inflammatory phenomena (Toth, 2007).  
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 Figure 1. Reverse cholesterol transport from extra-hepatic tissues to the liver by high-density lipoprotein (HDL). 
HDLr: HDL receptor; LCAT, lecithin cholesterol acyltransferase (Vaziri, 2003). 
 
1.4 HDL, APOA-II, AND LIPID METABOLISM 
 
The apolipoprotein A-II (apoA-II) is the 2nd major protein constituent of HDL (Blanco-
Vaca 2001). The mean apoA-II plasma concentration in normolipidemic humans is between 30-
35 mg/dl (Bu et al., 1994). More than 20% of patients with CHD have apoA-II concentrations 
between 40 and 60 mg/dl (Vu-Dac et al., 1996; Bu et al., 1994). Mainly, apoA-II is found 
associated with HDL. A small fraction of apoA-II can be found associated with chylomicrons 
and VLDL (Alaupovic et al., 1991). ApoA-II may play an important role in the HDL remodeling 
process (Blanco-Vaca et al., 2001). 
HDL is the smallest and most dense lipoprotein particle due to the high protein content 
(making up about 50% of HDL mass). ApoA-I and A-II are found in two main subpopulations of 
HDL; A-I-HDL (or Lp-I) contains only apoA-I, and A-I-A-II- HDL (or LpA-I-A-II) contains 
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both of the apolipoproteins). Both of these levels have been measured in recent epidemiologic 
studies (but have not been consistently measured in the past). Tailleux et al. (2002) conclude that 
apoA-I, LpA-I  and apoA-II, LpAI-A-II are frequently low in patients with atherosclerosis, but 
that “the same relationship between A-II, LpAI-A-II, and atherosclerosis has not been perfectly 
established as with apoA-I and LpA-I. Tailleux et al. (2002) also conclude that apoA-II cannot 
compensate for apoA-I deficiency in patients with apoA-I deficiency (who show premature 
atherosclerosis even in the presence of remaining apoA-II.)  
Barbaras et al. (1990) found that LpA-I may be more effective in capturing cholesterol 
from cells than Lp-A-I-A-II, suggesting that apoA-II may play an antagonistic role in cellular 
cholesterol efflux instead of sharing A-I’s agonistic role (using proteins from purified mouse 
adipose cells.) Another study in reconstituted HDL showed that diacylglycerol was produced (a 
step in cholesterol efflux) when A-I but not A-II bound adipose cells (Theret et al., 1990), 
supporting the antagonistic role of apoA-II. 
“The concentration of LpA1/A2 appears to be related to the synthesis of apoA-II in 
normolipidemic humans.” (Ikewaki et al., 1995). This was supported by a mouse model with a 
polymorphism that affected the efficiency of translation of apoA-II. In these mice, the 
LpA2/LpA1 ratio increased (Doolittle et al., 1990). 
Increasing the concentration of apoA-II in HDL showed a decrease in cholesterol efflux 
capacity in hepatoma cells in a study by Lagrost et al. (1995). Tailleux et al. (2002) report that 
this data confirms the role of apoA-II as an inhibitor of cellular efflux. Not all agree on an 
antagonistic role for apoA-II. A study using artificially reconstituted HDL with phospholipids 
and apolipoproteins found no difference in promotion of cholesterol efflux in HDL-cholesterol 
containing either apoA-I, A-II, or Cs (Mahlberg and Rothblat, 1992).  
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1.5 MOLECULAR ASPECTS OF APOA-II 
 
ApoA-II is made in the liver as a 100 amino acid precursor (preproapo A-II) (Eggerman 
et al. 1991). This precursor is cleaved to proapo A-II (18 amino acids), and the mature apoA-II 
protein is produced with a final 5 amino acid cleavage (Brewer et al. 1986). The production of 
apoA-II is regulated by positive and negative regulatory elements from -911 to +29 relative to 
the cap site of the gene (Chambaz et al. 1991) 
 . The apoA-II species seen in plasma include the major homodimer formed by 2 
polypetide chains of 77 amino acids linked by a disulfide bond at residue 6 (Brewer et al., 1972). 
Other minor species include the apoA-II-apoE heterodimer (in individuals with at least one 
APOE*2 or APOE*3 allele), the apoA-II-apoD heterodimer, and the apoA-II monomer (Brewer 
et al., 1972; Weisgraber and Mahley 1978; Borghini et al., 1991). 
There are at least two lipid-associating domains in apoA-II (between amino acid 12 and 
31 and 40 and 77 (Segrest et al., 1992). The amphipathic helices serve as lipid-associating 
protein detergent domains (Blanco-Vaca et al., 2001). 
The NCBI reference protein sequence for apoA-II is #NM_001643 and is 100 amino 
acids in length. The NCBI RNA locus is #NM_001643, and is 473 nucleotides in length.  
APOA2 has been mapped to chromosome 1 in region 1q21?1qter in humans (Li et al., 1988; 
Blanco-Vaca et al., 2001). ApoA-II is a member of the apolipoprotein superfamily which 
includes apoA-1, apoA-II, apoC’s, and apoE. APOA2 has 4 exons and 3 introns (see Figure 2) 
(Blanco-Vaca et al., 2001). 
 
 8 
 Figure 2. Structural organization of APOA2, including 4 exons and 3 introns. Figure adapted from Martin 
Campos et al. (2004). 
1.6 APOA2 POLYMORPHISMS 
APOA2 is one of the 3 dozen genes involved in lipid metabolism (apolipoproteins, 
lipoprotein receptors, and lipid processing enzymes). The estimated heritability (h2) for apoA-II 
is 0.69 (Berg, 1987). Studies of apoA-II in mice and humans have shown the antiatherogenic 
properties of apoA-II to be somewhat ambiguous.  
Fourteen variants in the APOA2 gene, plus the GT insertion/deletion polymorphism 
(close to the acceptor splice site of intron 2) have been reported by Fullerton et al. (2002) and 
summarized in the Seattle SNP Database for 3 populations (Jackson, MS; North Karelia, 
Finland; and Rochester, MN). A total of 4 variants (plus the GT repeat region) were reported in 
the Jackson population. (155C>G-MAF=0.04, 872C>T-MAF=0.33, 2233T>C-MAF=0.02, and 
2868A>C-MAF=0.02). Thirteen variants (plus the GT polymorphism) were observed in the 
Finnish population (155C>G-MAF=0.25, 872C>T-MAF=-0.31, 1218C>G-MAF=0.02, 
2038C>G-MAF=0.08, 2085T>C-MAF=0.02, 2115A>G-MAF=0.02, 2233T>C-MAF=0.15, 
2818T>C-MAF=0.08, 2868A>C-MAF=0.15, 2994T>C-MAF=0.02, 3027C>T-MAF=0.10, 
3092G>A-MAF=0.10, 3208A>G=MAF0.06). Twelve variants (plus the GT repeat region) were 
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observed in the Rochester population (155C>G-MAF=0.33, 201A>G-MAF=0.02, 872C>T-
MAF=-0.38, 2038C>G-MAF=0.17, 2115A>G-MAF=0.02, 2233T>C-MAF=0.17, 2818T>C-
MAF=0.17, 2868A>C-MAF=0.17, 2994T>C-MAF=0.15, 3027C>T-MAF=0.28, 3092G>A-
MAF=0.29, 3208A>G=MAF0.12). 
The GT repeat was identified by Weber and May, 1989. This polymorphism does not 
seem to have an effect on splicing (Blanco-Vaca et al., 2001). One SNP is a G-to-A change 
(termed APOA2Hiroshima) (location 2115; rs6413452 in the current study) that affects the donor 
splice site of intron 3. Homozygosity for this allele is associated with familial apoA-II deficiency 
(Deeb et al., 1990). This change does not seem to affect heart disease risk. Another SNP 
observed by Dupuy-Gorce et al. (1996) is a C-to-T change that modifies a BstNI restriction site 
near the acceptor splice site of intron 3 (2298C>T leu/leu synonymous change using Seattle 
Database nomenclature). 
1.7 ASSOCIATION OF APOA2 VARIANTS WITH PHENOTYPES 
It is well established that apoA-I has a protective role in CVD. The role of genetic 
variation in APOA2, however, is not clearly understood. There is one case of human apoA-II 
deficiency, caused by a gene mutation at the splice junction of exon 3 (site 2115 G>A). This 
mutation is expected to block the splicing of intron 3 from the primary transcript, preventing 
functional mRNA from forming in homozygous individuals. In this family, the apoA-II 
deficiency does not seem to have significant impact on lipid levels or on CHD risk (Deeb et al., 
1990). 
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Male patients with CHD have been studied for association with CA repeat region 
(position 1671), but it showed no association (Shadrina et al., 1997). 
1.8 GENETIC VARIANTS AND COMMON TRAITS 
Low HDL-cholesterol is a common trait in the general population and could be explained 
by common alleles in candidate loci, illustrating the “common trait-common variant” hypothesis. 
(Knoblauch et al., 2004; Morabia et al., 2003). Hegele et al. (1997) suggested that small genetic 
effects of common variants may be a more realistic genetic model for plasma lipoprotein 
variation. Other studies suggest that multiple rare variants are associated with low HDL-
cholesterol levels, illustrating the “common trait-rare variant” hypothesis (Cohen et al., 2004). 
Cohen et al. (2004) studied the effects of rare alleles in ABCA1, APOA1 and LCAT genes 
on plasma HDL-cholesterol levels in the general population and found that nonsynonymous 
sequence variants were significantly more common in the low HDL-cholesterol group than in the 
high HDL-cholesterol group. (One SNP was found in the low HDL-cholesterol group that was 
not found in the high HDL-cholesterol group.) 
Sequencing-based studies have been used to identify both the phenotypic effect of rare 
variants, and common variants with a modest effect. Crawford et al. (2006) have shown that by 
resequencing subjects with extreme quantitative traits, potentially medically relevant variants can 
be detected. They conclude that to fully understand the variety of alleles that affect human 
phenotypes, however, many different sequencing and genotyping methods may be necessary. 
 11 
1.9 SPECIFIC AIMS 
The objective of this study was to evaluate the genetic variation in the APOA2 gene in 
relation to HDL-cholesterol levels in two well-characterized epidemiological samples of 788 
African blacks from Benin City, Nigeria and 624 U.S. Non-Hispanic Whites (NHWs) from 
Colorado. Because APOA2 is a biological candidate for HDL-cholesterol levels, its common 
and/or rare variants are hypothesized to contribute to variation in HDL-cholesterol levels. 
Step 1: APOA2 was resequenced in individuals with HDL-cholesterol in the upper 5th 
percentile (47 NHWs and 48 Blacks) and in the lower 5th percentile (48 NHWs and 47 Blacks). 
This allows us to identify rare variants in addition to common variants. The variants that are 
unique to one group or the other, or common to both groups that may be over-represented or 
under-represented in one group may have biological significance. 
Step 2: Common tagSNPs and rare variants (MAF <5%) were screened in the entire 
NHW and Black population (individuals with varying levels of HDL-cholesterol). The effects of 
both rare and common variants on HDL-cholesterol levels were determined. 
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2.0  SUBJECTS AND METHODS 
2.1 SUBJECTS 
2.1.1 Sample Populations 
Table 1 summarizes the subjects used in this study. Samples from the African Black 
population were recruited from Benin City, Nigeria as part of a study on CHD risk factors in 
Blacks. Demographic and health information was gathered from participants during the initial 
study. The subjects from Benin City were recruited from Junior and Senior staff in government 
ministries (representing different salary grades.) Detailed information about the study population 
can be found in Bunker et al. (1995, 1996). 
 
Table 1.  Sample populations 
 
Population Men (%) Women (%) Total (%) 
African blacks 502 (62.4) 302 (37.6) 804 (53.8) 
U.S. whites 322 (46.6) 369 (53.4) 691 (46.2) 
Total 824 (55.1) 671 (44.9) 1,495 (100) 
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Samples from Non-Hispanic Whites (NHWs) were drawn from the San Luis Valley 
Southern Colorado Diabetes Study. All subjects who were included in the current study were 
normoglycemic and a more detailed description of the sample population can be found in 
Hamman et al. (1989) and Rewers et al. (1993).  
Total HDL-cholesterol was determined enzymatically after dextran sulfate magnesium 
precipitation (Harris et. al 1998). 
2.2 DNA SEQUENCING 
DNA was extracted from clot samples (Black population) and from buffy coat (NHW 
population) using standard procedures. Individuals with serum HDL-cholesterol in the upper 5th 
percentile (47 white and 48 black) and in the lower 5th percentile (48 white and 47 black) were 
selected to be used to screen for common and rare variants by resequencing of DNA samples for 
the entire APOA2. Of 95 NHW individuals, 47 were females (23 with high HDL levels and 24 
with low HDL levels); 48 were males (24 with high HDL levels and 24 with low HDL levels). 
Of 95 Black individuals, 48 were females (24 with high HDL levels and 24 with low HDL 
levels); 47 were males (24 with high HDL levels and 23 with low HDL levels). Refer to Table 2 
for a summary of the population characteristics including age, BMI, LDL-, HDL-, and total 
cholesterol and triglyceride levels in NHWs and Blacks for both high HDL and low HDL 
subgroups. 
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 Table 2. Biometric and quantitative data (mean±SD) of NHW and Black samples used for DNA 
sequencing. 
 
Variable High HDL (n =47) Low HDL (n =48) p -value High HDL (n =48) Low HDL (n =47) p -value
Sex (M/F) 24/23 24/24 0.92 24/24 23/24 0.92
Age (years) 55.45 ± 9.80 53.03 ± 10.54 0.25 41.29 ± 8.72 40.87 ± 7.16 0.8
BMI (kg/m2) 23.17 ± 3.17 27.35±3.90 <0.001 22.06 ± 4.71 23.91 ± 5.51 0.08
Total cholesterol 
(mg/dl) 227.34±51.76 208.81±44.65 0.06 201 ± 39.68 141.68 ± 31.03 <0.001
LDL cholesterol 
(mg/dl) 126.84±46.95 136.95±41.28 0.28 112.55 ± 39.75 95.04 ± 28.28 0.02
HDL cholesterol 
(mg/dl) 77.68±13.32 31.81±4.37 <0.001 76.05 ± 7.53 25.51 ± 5.66 <0.001
Triglycerides 
(mg/dl) 114.09±60.88 240.21±153.22 <0.001 61.98 ± 19.85 95.79 ± 73.21 0.003
NHWs (n=95) Blacks (n=95)
 
We used the publicly available information from the Seattle SNPs database 
(http://pga.mbt.washington.edu/) to order M13-tagged primers used to resequence APOA2. The 
M13-tagged primers that were used to produce overlapping resequencing amplicons are 
displayed in Table 3. 
 
Table 3 APOA2 Polymerase Chain Reaction (PCR) Primers 
 
PCR 
Amplicons Forward Primer Reverse Primer
1 5'-tgtaaaacgacggccagtCAGCCTGAGCAACAAGAGCA-3' 5'-caggaaacagctatgaccCAGGAAGCAGGATTCCAAGTT-3'
2 5'-tgtaaaacgacggccagtTCAACCCTGTCCCTGATTTC-3' 5'-caggaaacagctatgaccCACCAGCACATTCTCCCTTT-3'
3 5'-tgtaaaacgacggccagtGTTGTGGAGAGGGAGAGAGC-3' 5'-caggaaacagctatgaccAGGCCCAGTTCTTGCTGTTC-3'
4 5'-tgtaaaacgacggccagtGCAAGGACCTGATGGAGAAG-3' 5'-caggaaacagctatgaccGCACCCTCATCCTGTCATTT-3'
5 5'-tgtaaaacgacggccagtCTAGAGCTCCTGTCCCTAC-3' 5'-caggaaacagctatgaccTGCCTGGTCTAGATAAGAGG-3'
Internal SEQ 
primer 5'-AAATGACAGGATGAGGGTGC-3'
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These primers produce 5 overlapping amplicons ranging in size from 811 to 906 base 
pairs (bps) to cover the entire gene, plus ~ 1.1 kb of 5’ flanking region (putative promoter 
region) and ~ 900 bps of 3’ flanking region. About 3.3 kb of genomic fragment were amplified 
and sequenced overall. Initially, all 5 amplicons were sequenced in one direction (forward). 
Subsequently, two amplicons were sequenced in the other direction (reverse) in order to fill the 
gaps. Despite both directional sequencing, a small gap was still observed for amplicon #5. In 
order to fill this small gap, we designed (Primer3 Software, version 0.4.0 
http://Frodo.wi.mit.edu) and used an internal sequencing primer.  
The PCR was performed on a thermal cycler with a heated lid (GeneAmp PCR System 
9700, Applied Biosystems). The PCR (Polymerase Chain Reaction) reaction and cycling 
conditions are given in Table 4.  
Table 4. PCR Reaction and Cycling Conditions 
 
PCR Reaction (total volume 25 µL) PCR conditions 
DNA 3.0 µL        
 
1. 95˚C for 5 minutes  
 
2. 95˚C for 45 sec. 
3. 61˚C for 45 sec.     }  
4. 72˚C for 1 min. 
      (2-4 for 40 cycles)   
    
5. 72˚C for 10 min. 
6. Cool to 4˚C 
dH2O 11.75 µL 
10x BufferGold 2.5 µL 
MgCl2 (25 mM) 3.0 µL 
dNTPs (1.25 mM) 3.8 µL 
Forward Primer (20mM) 0.4 µL 
Reverse Primer (20mM) 0.4 µL 
TaqPolymerase (5U/µL) 0.15 µL 
 
Gel electrophoresis was used to check for the success of the amplification of all PCR 
samples. For each sample, 7µL of PCR product was combined with 7µL of loading buffer and 
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6µL distilled water, and loaded into a 96-well pre-cast agarose gel (Invitrogen™ E-Gel® 96 2% 
with SYBR® Safe) and run for 8 minutes using the EG program on the electrophoresis base 
(Invitrogen™ E-Base™). For a small number of samples that failed initial amplification, 
reamplification and confirmation was performed using regular agarose gels. For this purpose, 
7µL of PCR product was combined with 5µL of loading buffer and loaded into 2% agarose gel 
in TBE buffer (tris, boric acid, and disodium EDTA dihydrate) and stained with ethidium 
bromide (Amresco). Electrophoresis was run for about 25 minutes at 250V. Both 96-well pre-
cast gels and regular agarose gels were visualized using a UV transilluminator. 
The amplified samples were sent for capillary sequencing (Genomic Services of 
Agencourt Bioscience Corporation, Beverly, MD). Two programs were used to align and analyze 
the sequencing results; Sequencher version 4.7 (Gene Codes Corporation, Ann Arbor, MI), and 
Variant Reporter version 1.0 (Applied Biosystems, Foster City, CA). 
2.3 GENOTYPING 
2.3.1 Common SNPs 
For common SNPs (MAF≥5%), we either ordered available pre-made TaqMan SNP 
genotyping assays or requested custom designed assays. Seven assays were available as pre-
made TaqMan SNP genotyping assays. Two of four requested custom assays passed the quality 
control requirements and were used in our study. Table 5 details a total of 9 assays that were 
analyzed in either the African black or NHW population or both.  
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 2.3.1.1 TaqMan analysis 
Table 5. TaqMan® SNP Genotyping Assays 
 
APOA2 reference SNP ID* TaqMan® Assay Type Assay ID Population 
rs3829793 Pre-made C__27495574_10  Both 
rs5082 Pre-made C__11453334_10 Both 
rs5087 Pre-made C__11453973_20 NHWs 
rs6413452 Pre-made C__29505396_10 NHWs 
rs6413453 Pre-made C__25770132_10 Both 
rs5088 Pre-made C__11453980_10 Blacks 
rs12721035 Pre-made C__31430618_10 NHWs 
rs12143180 Custom made AoA2-2994 Both 
3251 Custom made ApA2-3251 NHWs 
 
*Reference SNP ID number was used whenever the SNP was present in public databases. For 
newly identified variants, we used the same nomenclature as the SeattleSNPs database, based on 
the location in the reference DNA sequence (Accession # AY100524) 
 
 The TaqMan procedure involves amplification of the product and endpoint reading using 
the ABI Prism 7900HT Sequence Detection System (Applied Biosystems). TaqMan Genotyping 
Master Mix and Assay is added to 384-well plates containing dried whole genome amplified 
DNA. The Genotyping Assay contains sequence-specific forward and reverse primers, one 
TaqMan minor groove binder (MGB) probe labeled at the 5’ end with VIC dye and one TaqMan 
MGB probe labeled at the 5’ end with FAM dye to detect the alternative alleles. On the 3’ end of 
the probes, a nonfluorescent quencher (NFQ) is attached. PCR amplification was done using a 
PTC-200 MJThermal Cycler (Biorad) or a GeneAmp 9700 (Applied Biosystems). The cycling 
conditions are displayed in Table 6. 
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Table 6. Thermal Cycler Conditions for TaqMan 
 
Times and Temperatures 
Initial Step Denaturation Primer Annealing & 
Extension 
HOLD 50 Cycles 
10 min @95°C 15 sec @95°C 1 min @ 60°C 
 
 
Each TaqMan MGB probe anneals to the target sequence harboring the SNP of interest 
during the annealing step. Then, AmpliTaq Gold DNA polymerase cleaves the probes that 
hybridize to the target sequence. During this process, the reporter dye is separated from the 
quencher dye, releasing fluorescence. Fluorescence is suppressed if probes do not hybridize to 
the target sequence and the reporter dye does not separate from the quencher dye. Because of the 
selective annealing of the TaqMan MGB probes, discrimination of alleles is possible. 
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 Figure 3. Illustration of TaqMan probe-target matches and mismatches. Wang et al., 2006. 
2.3.2 Rare Variants 
2.3.2.1 Restriction Fragment Length Polymorphism (RFLP) 
Restriction Fragment Length Polymorphism (RFLP) is a technique than can be used to 
detect sequence alterations using restriction enzymes. Restriction enzymes or restriction 
endonucleases can recognize and cut DNA in the presence of a specific short sequence (usually a 
palindromic segment of 4-8 base pairs). The DNA can then be separated in gel electrophoresis, 
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allowing visualization of the fragments. In this way, the presence or absence of a specific 
nucleotide can be confirmed. 
In our experiment, we searched for a possible RFLP site for all of our variants using 
NEBcutter V2.0 (New England Biolabs, Ipswitch, MA). We ordered RFLP primers and enzymes 
when the following conditions were met; a polymorphic restriction site concerning our target 
variant was present; there are not too many nearby non-polymorphic restriction sites that may 
hamper the gel-based allelic discrimination; the restriction site flanking sequences allow us to 
design successful PCR primers. Those three conditions were met for 4 variants (159, 336, 1055, 
and 1569). 
The PCR primers that were used are displayed in Table 7. Reaction mixture quantities 
and conditions are given in Table 8. Agarose gel electrophoresis was used to confirm the 
successful amplification of PCR products using the same approach as for sequencing amplicons. 
 
Table 7. RFLP PCR Primers 
 
 
APOA2 variant Forward Primer Reverse Primer 
159 5’-TGAGCAACAAGAGCAAAACTC-3’ 5’-CAGAAGCTTTTGTATCTTTCACC-3’
336 5’-TTCACCCAAATGCTTTGAAC-3’ 5’-TGGCAGGAAAAGAGGTGAAT-3’
1055 5’-CCATCACCATGAGTCTTCCA-3’ 5’-TCTGTCCTTGGTGTCTGTGC-3’
1569 5’-AAAAGGGAGAATGTGCTGGT-3’ 5’-GGTCCACAGCAGTGAATCCT-3’
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 Table 8. PCR Reaction and Cycling Conditions for RFLP 
 
 
Reaction Conditions Cycling Conditions 
(GeneAmp 9700 thermal cycler) 
DNA 3.0 µL       
     95˚C for 5 minutes 
95˚C for 45 sec. 
60/61˚C for 45 sec.   } 40 cycles 
72˚C for 1 min. 
      72˚C for 10 min. 
      Cool to 4˚C 
dH2O 12.25/11.75 µL 
10x BufferGold 2.5 µL 
MgCl2 (25 mM) 2.5/3.0 µL 
dNTPs (1.25 mM) 3.8 µL 
Forward Primer  0.4 µL 
Reverse Primer 0.4 µL 
TaqPolymerase (5U/µL) 0.15 µL 
 
To confirm the variants that were detected by sequencing, we individually amplified the 
samples with known genotypes (all known heterozygotes and selected known wild-type 
homozygotes) and tested our RFLP method. After the confirmation of the variant and the success 
of the RFLP, we tested the pre- and post-PCR pooling strategy by combining different numbers 
of samples (either pre-PCR DNA or post-PCR amplicons) ranging from 5 to 10 samples. We 
used a higher volume of PCR for the digestion reaction when we pooled post-PCR products 
(between 20 and 24 µL of pooled sample was used). 
From individual samples and pre-PCR pooled samples, we combined 17 μL of each 
sample with 13 μL of master mix including: 9.5μL dH2O, 3 μL 10x buffer, and 0.5 μL of the 
restriction enzyme. The restriction enzyme and overnight incubation temperature used for 4 rare 
variants are given in Table 9. 
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 Table 9. Restriction Enzyme and Overnight Temperature used in RFLP 
 
APOA2 variant Enzyme used for 
digestion 
Expected fragments Overnight incubation 
temperature 
159C>G CviKI-1 129+85 vs. 129+65+20 37°C 
336T>G MspI 200 vs. 113+87 37°C 
1055C>T BsrI 99+87 vs. 186 65°C 
1569T>C MspI 218 vs.128+90 37°C 
 
Fifteen μL of digested product was combined with 7μL loading buffer and loaded to 2% 
or 3% agarose gel (depending on the size difference of expected fragments) with ethidium 
bromide and electrophoresis was run for ~30-50 minutes at 150V. 
2.4 STATISTICAL METHODS 
Allele frequencies were determined by direct allele counting. Concordance of the 
genotype distribution to Hardy-Weinberg equilibrium was tested using a χ2 goodness-of-fit test 
for each variant. Fisher’s exact test and standard Z-test of two binomial proportions were used to 
compare the genotype and allele frequencies, respectively. Linkage disequilibrium (LD) pattern 
and tagSNPs were determined using the Haploview version 3.32 
(http://www.broad.mit.edu/mpg/haploview/). All dependent quantitative variables were 
transformed (using either log or square root transformation) to reduce the effects of non-
normality whenever necessary. The significant covariates for each dependent variable were 
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identified using stepwise regression in both directions. The most parsimonious set of covariates 
was determined separately for males and females within each ethnic group. One-way analysis of 
variance (ANOVA) was performed separately for males and females within each ethnic group to 
test for the effects of genotypes on the means of the quantitative traits (transformed and adjusted 
when necessary). All computations were performed using the R statistical software package 
(version 2.3.1, http://www.r-project.org). A p-value of less than 0.05 was considered as 
suggestive evidence of association. 
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3.0  RESULTS 
3.1 DNA SEQUENCING OF THE APOA2 GENE 
Complete APOA2 sequencing was performed on DNA samples from 95 African Black 
and 95 American NHW individuals with the highest and lowest HDL levels. A total of 26 
sequence variants were identified, including a microsatellite (dinucleotide repeat marker) in 
intron 2. Of the 26 variants, 14 were already reported in publicly available databases. Of the 25 
single nucleotide substitutions (no indels detected), 9 were observed only in the NHWs, and 7 
were observed only in Blacks (Table 10). Nine variants were seen in both NHWs and Blacks. 
The GT dinucleotide repeat marker was not evaluated in detail due to the difficulties in doing so 
using the software packages we had. Figure 4 is a schematic representation of the location of the 
variants identified in this study. 
Among the 12 newly identified variants, only one had a MAF of 5% and the remaining 
11 variants had less than 5% MAF. Seven variants had a MAF of less than 1%. Nine variants 
were located in the putative promoter region. Only one variant was in the coding region (exon 4, 
rs5088, 2298C>T), and was a silent mutation causing a synonymous amino acid change at 
position 83 (leucine/leucine). The remaining variants were in either intronic (8 variants including 
the microsatellite) or in the 3’-flanking regions (8 variants). Chromatograms illustrating the 12 
new variants are shown in Figure 5 and Figure 6. 
 25 
Table 10. APOA2 variants identified in our study. *Location based on DNA reference sequence accession # 
AY100524 (the microsatellite marker is not included in this table.) 
 
APOA2 Variant* rs (CHIP&GB) Population Location MAF(NHWs) MAF(Blacks) 
155G>C rs3829793 Both promoter 0.321 0.063 
159C>G new variant NHWs promoter 0.011 --- 
336T>G new variant Blacks promoter 0.005 --- 
470G>A new variant Blacks promoter --- 0.005 
589C>T new variant Blacks promoter --- 0.021 
772C>T new variant NHWs promoter 0.016 --- 
872T>C rs5082 Both promoter 0.405 0.195 
898A>G new variant NHWs promoter 0.005 --- 
1055C>T new variant Blacks promoter --- 0.042 
1569T>C new variant Blacks intron 2 --- 0.005 
1638C>T new variant Blacks intron 2 --- 0.027 
2038G>C rs5085 Both intron 3 0.168 0.095 
2085C>T rs5087 NHWs intron 3 0.005 --- 
2115G>A rs6413452 NHWs intron 3 0.016 --- 
2218A>C new variant NHWs intron 3 0.005 --- 
2233C>T rs6413453 Both intron 3 0.084 0.005 
2298C>T rs5088 Blacks exon 4 --- 0.026 
2547G>T new variant Blacks 3' flanking --- 0.005 
2818C>T rs12143241 Both 3' flanking 0.168 0.095 
2868C>A rs12721036 Both 3' flanking 0.084 0.005 
2994C>T rs12143180 Both 3' flanking 0.163 0.053 
3027T>C rs685 Both 3' flanking 0.200 0.095 
3092A>G rs17244530 Both 3' flanking 0.197 0.083 
3208G>A rs12721035 NHWs 3' flanking 0.038 --- 
3251A>G new variant NHWs 3' flanking 0.048 --- 
 
 
 
 
Figure 4. Schematic representation of the APOA2 gene, showing the location of variants identified in this study. 
Black arrows represent variants found in both NHWs and Blacks; red arrows represent variants found in only 
NHWs; blue arrows represent variants found in only Blacks. Figure adapted from Martin Campos et al., 2004. 
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 Figure 5. Chromatograms for variants at positions 159, 336, 470, 589, 772, and 898. 
 
 27 
 Figure 6. Chromatograms for variants at positions 1055, 1569, 2547, 1638, 2218, and 3251. 
 
 28 
3.2 GENOTYPE DISTRIBUTION OF APOA2 VARIANTS BETWEEN HIGH- AND 
LOW-HDL GROUPS 
3.2.1 American Non-Hispanic Whites 
 Out of 18 variants (excluding the microsatellite) present in NHWs, 9 had MAF of >5%; 5 
had MAF between 1% and 5%; and 4 had a MAF of less than 1%. Six out of 18 variants were 
newly identified, and of those, one had 5% MAF and the rest had less than 5% MAF. Table 11  
and Table 12 compare the high- and low-HDL groups for variants present in heterozygous and/or 
homozygous states and for their genotype distribution and allele frequencies, respectively. We 
found a significant difference of allele frequencies for 2233C>T/rs6413453 and 
2868C>A/rs12721036 SNPs between the high- and low- HDL groups (p=0.038 for each). Those 
two SNPs were later found to be closely linked to each other (see LD analysis section). 
In NHWs, we observed 2 rare variants (excluding unconfirmed 336T>G) only in the low 
HDL group (898A>G and 2085C>T), and 1 rare variant only in the high HDL group (2218A>C). 
For 6 of 14 SNPs found in both groups, homozygosity was observed only in the low HDL group 
(3251A>G, 2038G>C, 2233C>T, 2818C>T, 2868C>A, and 2994C>T), although heterozygotes 
were seen in both high and low HDL groups. There was no variant that was observed in 
homozygosity in only the high HDL group. 
Of the 48 individuals with low plasma levels of HDL, 7 (14.6%) had either rare variants 
not present in the high HDL group (N=3) or carried between 1 and 4 variants that were observed 
in the homozygous state only in the low HDL group (N=4). In contrast, of the 47 individuals 
with high plasma levels of HDL, only 1 subject (2.1%) had a rare variant not present in the low 
HDL group, and none carried variants that were homozygous only in the high HDL group. 
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Table 11. Distribution of APOA2 variants in high and low HDL groups in NHWs. “Het” and “Hom” 
represent individuals heterozygous and homozygous for the minor allele, respectively. 
 
Variants
Het Hom Het Hom
rare 
(MAF<5%)
159C>G + - + -
336T>G - - + -
772C>T + - + -
898A>G - - + -
2085C>T - - + -
2115G>A + - + -
2218A>C + - - -
3208G>A + - + -
3251A>G + - + +
common 
(MAF≥5%)
155G>C + + + +
872T>C + + + +
2038G>C + - + +
2233C>T + - + +
2818C>T + - + +
2868C>A + - + +
2994C>T + - + +
3027T>C + + + +
3092A>G + + + +
Low HDL (n= 48)
Non-Hispanic Whites
High HDL (n =47)
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Table 12. Genotype and Allele Frequencies of APOA2 Variants in High and Low-HDL Groups in NHWs. 
n (%) n (%) n (%) n (%) n (%) n (%)
GG 25 (53.19) 19 (39.58) 44 46.32 CC 45 (97.83) 47 (97.92) 92 97.87
GC 18 (38.30) 23 (47.92) 41 43.16 CG 1 (2.17) 1 (2.08) 2 2.13
CC 4 (8.51) 6 (12.50) 10 10.53 GG 0 (0.00) 0 (0.00) 0 0.00
47 48 95 46 48 94
G 0.723 0.635 0.679 C 0.989 0.990 0.989
C 0.277 0.365 0.321 GG 0.011 0.010 0.011
n (%) n (%) n (%) n (%) n (%) n (%)
TT 47 (100.00) 47 (97.92) 94 98.95 CC 46 (97.87) 46 (95.83) 92 96.84
TG 0 (0.00) 1 (2.08) 1 1.05 CT 1 (2.13) 2 (4.17) 3 3.16
GG 0 (0.00) 0 (0.00) 0 0.00 TT 0 (0.00) 0 (0.00) 0 0.00
47 48 95 47 48 95
T 1.000 0.990 0.995 C 0.989 0.979 0.984
G 0.000 0.010 0.005 T 0.011 0.021 0.016
n (%) n (%) n (%) n (%) n (%) n (%)
TT 15 (32.61) 16 (33.33) 31 32.98 AA 47 (100.00) 47 (97.92) 94 98.95
TC 25 (54.35) 24 (50.00) 49 52.13 AG 0 (0.00) 1 (2.08) 1 1.05
CC 6 (13.04) 8 (16.67) 14 14.89 GG 0 (0.00) 0 (0.00) 0 0.00
46 48 94 47 48 95
T 0.598 0.583 0.590 A 1.000 0.990 0.995
C 0.402 0.417 0.410 G 0.000 0.010 0.005
n (%) n (%) n (%) n (%) n (%) n (%)
GG 33 (70.21) 33 (68.75) 66 69.47 CC 47 (100.00) 47 (97.92) 94 98.95
GC 14 (29.79) 12 (25.00) 26 27.37 CT 0 (0.00) 1 (2.08) 1 1.05
CC 0 (0.00) 3 (6.25) 3 3.16 TT 0 (0.00) 0 (0.00) 0 0.00
47 48 95 47 48 95
G 0.851 0.813 0.832 C 1.000 0.990 0.995
C 0.149 0.188 0.168 T 0.000 0.010 0.005
Position 155, rs3829793 Position 159, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 336, new variant Position 772, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 872 rs5082 Position 898, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 2038, rs5085 Position 2085, rs5087
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
p =0.447
p =0.192
p =1.000
p =0.976
p =1.000 p =1.000
p =0.315 p =0.571
p =0.885
p =0.746
p =1.000
p =0.315
p =0.299
p =0.477
p =1.000
p =0.315
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Table 12. (Continued) 
 
n (%) n (%) n (%) n (%) n (%) n (%)
GG 45 (95.74) 46 (97.87) 91 96.81 AA 46 (97.87) 48 (100.00) 94 98.95
GA 2 (4.26) 1 (2.13) 3 3.19 AC 1 (2.13) 0 (0.00) 1 1.05
AA 0 (0.00) 0 (0.00) 0 0.00 CC 0 (0.00) 0 (0.00) 0 0.00
47 47 94 47 48 95
G 0.979 0.989 0.984 A 0.989 1.000 0.995
A 0.021 0.011 0.016 C 0.011 0.000 0.005
n (%) n (%) n (%) n (%) n (%) n (%)
CC 43 (91.49) 37 (77.08) 80 84.21 CC 33 (70.21) 33 (68.75) 66 69.47
CT 4 (8.51) 10 (20.83) 14 14.74 CT 14 (29.79) 12 (25.00) 26 27.37
TT 0 (0.00) 1 (2.08) 1 1.05 TT 0 (0.00) 3 (6.25) 3 3.16
47 48 95 47 48 95
C 0.957 0.875 0.916 C 0.851 0.813 0.832
T 0.043 0.125 0.084 T 0.149 0.188 0.168
n (%) n (%) n (%) n (%) n (%) n (%)
CC 43 (91.49) 37 (77.08) 80 84.21 CC 34 (72.34) 33 (68.75) 67 70.53
CA 4 (8.51) 10 (20.83) 14 14.74 CT 13 (27.66) 12 (25.00) 25 26.32
AA 0 (0.00) 1 (2.08) 1 1.05 TT 0 (0.00) 3 (6.25) 3 3.16
47 48 95 47 48 95
C 0.957 0.875 0.916 C 0.862 0.813 0.837
A 0.043 0.125 0.084 T 0.138 0.188 0.163
n (%) n (%) n (%) n (%) n (%) n (%)
TT 34 (72.34) 28 (58.33) 62 65.26 AA 32 (71.11) 28 (59.57) 60 65.22
TC 11 (23.40) 17 (35.42) 28 29.47 AG 11 (24.44) 16 (34.04) 27 29.35
CC 2 (4.26) 3 (6.25) 5 5.26 GG 2 (4.44) 3 (6.38) 5 5.43
47 48 95 45 47 92
T 0.840 0.760 0.800 A 0.833 0.766 0.799
C 0.160 0.240 0.200 G 0.167 0.234 0.201
Position 2115, rs6413452 Position 2218, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 2233, rs6413453 Position 2818, rs12143241
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 2868, rs12721036 Position 2994,  rs12143180
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
TOTAL High HDL Low HDL TOTAL
p =1.000 p =0.495
p =0.560 p =0.315
p =0.251p =0.165
p =0.368 p =0.554
p =0.357
p =0.364p =0.116
p =0.038
Position 3027, rs685 Position 3092, rs17244530
High HDL Low HDL
p =0.477
p =0.299p =0.116
p =0.038
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Table 12. ( ontinued) 
 
C
n (%) n (%) n (%) n (%) n (%) n (%)
GG 43 (95.56) 43 (89.58) 86 92.47 AA 41 (91.11) 44 (91.67) 85 91.40
GA 2 (4.44) 5 (10.42) 7 7.53 AG 4 (8.89) 3 (6.25) 7 7.53
AA 0 (0.00) 0 (0.00) 0 0.00 GG 0 (0.00) 1 (2.08) 1 1.08
45 48 93 45 48 93
G 0.978 0.948 0.962 A 0.956 0.948 0.952
A 0.022 0.052 0.038 G 0.044 0.052 0.048
TOTAL High HDL Low HDL TOTAL
p =0.277 p =0.808
p =0.437 p =0.851
Position 3208, rs12721035 Position 3251, new variant
High HDL Low HDL
 
3.2.2 African Blacks 
Of 16 variants present in Blacks (excluding the microsatellite), 7 had MAF>5%; 4 had 
MAF between 1% and 5%; and 5 had a MAF<1%. Six of the 16 variants were newly identified 
and of those, one had a MAF of 4% and the rest had less than 4% MAF. Table 13 and Table 14 
compare the high- and low-HDL groups for variants present in heterozygous and/or homozygous 
states and for their genotype distribution and allele frequencies, respectively. We found no 
significant difference of allele frequencies of APOA2 variants between the high- and low- HDL 
groups. 
In Blacks, 3 rare variants were observed only in the low HDL group (2233C>T, 
2547G>T, 2868C>A) and 2 rare variants were observed only in the high HDL group (470G>A 
and 1569T>C). Eleven SNPs were present in both high HDL and low HDL groups, but 
homozygosity was observed only in the low HDL group for 6 variants (155G>C, 2038G>C, 
2818C>T, 2994C>T, 3027T>C, 3092A>G) and only in the high HDL group for 1 variant 
(872T>C). 
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Of the 47 individuals with low plasma levels of HDL, 4 (8.5%) had either rare variants 
not present in the high HDL group (N=3) or carried 5 variants that were observed in the 
homozygous state only in the low HDL group (N=1). Of the 48 individuals with high plasma 
levels of HDL, 3 (6.3%) had either a rare variant not present in the low HDL group (N=2), or 
carried a variant that was homozygous only in the high HDL group (N=1). 
 
Table 13. Distribution of APOA2 variants in high and low HDL groups in African Blacks. “Het” and 
“Hom” represent individuals heterozygous and homozygous for the minor allele, respectively. 
 
Variants
Het Hom Het Hom
rare 
(MAF<5%)
470G>A + - - -
589C>T + - + -
1055C>T + - + -
1569T>C + - - -
1638C>T + - + -
2233C>T - - + -
2298C>T + - + -
2547G>T - - + -
2868C>A - - + -
common 
(MAF≥5%)
155G>C + - + +
872T>C + + + -
2038G>C + - + +
2818C>T + - + +
2994C>T + - + +
3027T>C + - + +
3092A>G + - + +
Blacks
High HDL (n =48) Low HDL (n =47)
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Table 14. Genotype and Allele Frequencies of APOA2 Variants in High and Low-HDL Groups in Blacks. 
n (%) n (%) n (%) n (%) n (%) n (%)
GG 41 (85.42) 43 (91.49) 84 88.42 GG 47 (97.92) 47 (100.00) 94 98.95
GC 7 (14.58) 3 (6.38) 10 10.53 GA 1 (2.08) 0 (0.00) 1 1.05
CC 0 (0.00) 1 (2.13) 1 1.05 AA 0 (0.00) 0 (0.00) 0 0.00
48 47 95 48 47 95
G 0.927 0.947 0.937 G 0.990 1.000 0.995
C 0.073 0.053 0.063 A 0.010 0.000 0.005
n (%) n (%) n (%) n (%) n (%) n (%)
CC 47 (97.92) 44 (93.62) 91 95.79 TT 31 (64.58) 28 (59.57) 59 62.11
CT 1 (2.08) 3 (6.38) 4 4.21 TC 16 (33.33) 19 (40.43) 35 36.84
TT 0 (0.00) 0 (0.00) 0 0.00 CC 1 (2.08) 0 (0.00) 1 1.05
48 47 95 48 47 95
C 0.990 0.968 0.979 T 0.813 0.798 0.805
T 0.010 0.032 0.021 C 0.188 0.202 0.195
n (%) n (%) n (%) n (%) n (%) n (%)
CC 44 (91.67) 43 (91.49) 87 91.58 TT 46 (97.87) 47 (100.00) 93 98.94
CT 4 (8.33) 4 (8.51) 8 8.42 TC 1 (2.13) 0 (0.00) 1 1.06
TT 0 (0.00) 0 (0.00) 0 0.00 CC 0 (0.00) 0 (0.00) 0 0.00
48 47 95 47 47 94
C 0.958 0.957 0.958 T 0.989 1.000 0.995
T 0.042 0.043 0.042 C 0.011 0.000 0.005
n (%) n (%) n (%) n (%) n (%) n (%)
CC 44 (93.62) 45 (95.74) 89 94.68 GG 38 (79.17) 40 (85.11) 78 82.11
CT 3 (6.38) 2 (4.26) 5 5.32 GC 10 (20.83) 6 (12.77) 16 16.84
TT 0 (0.00) 0 (0.00) 0 0.00 CC 0 (0.00) 1 (2.13) 1 1.05
47 47 94 48 47 95
C 0.968 0.979 0.973 G 0.896 0.915 0.905
T 0.032 0.021 0.027 C 0.104 0.085 0.095
p= 0.650
p =1.000 p =0.412
p=0.653
p =1.000
p= 0.976
p =1.000
p= 0.315
p= 0.303 p= 0.799
p =0.597p =0.362
p =1.000p =0.317
p= 0.575 p= 0.315
Position 1638, new variant Position 2038, rs5085
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 1055, new variant Position 1569, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 589, new variant Position 872, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 155, rs3829793 Position 470, new variant
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
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Table 14. (Continued) 
n (%) n (%) n (%) n (%) n (%) n (%)
CC 48 (100.00) 46 (97.87) 94 98.95 CC 45 (93.75) 45 (95.74) 90 94.74
CT 0 (0.00) 1 (2.13) 1 1.05 CT 3 (6.25) 2 (4.26) 5 5.26
TT 0 (0.00) 0 (0.00) 0 0.00 TT 0 (0.00) 0 (0.00) 0 0.00
48 47 95 48 47 95
C 1.000 0.989 0.995 C 0.969 0.979 0.974
T 0.000 0.011 0.005 T 0.031 0.021 0.026
n (%) n (%) n (%) n (%) n (%) n (%)
GG 48 (100.00) 46 (97.87) 94 98.95 CC 38 (79.17) 40 (85.11) 78 82.11
GT 0 (0.00) 1 (2.13) 1 1.05 CT 10 (20.83) 6 (12.77) 16 16.84
TT 0 (0.00) 0 (0.00) 0 0.00 TT 0 (0.00) 1 (2.13) 1 1.05
48 47 95 48 47 95
G 1.000 0.989 0.995 C 0.896 0.915 0.905
T 0.000 0.011 0.005 T 0.104 0.085 0.095
n (%) n (%) n (%) n (%) n (%) n (%)
CC 48 (100.00) 46 (97.87) 94 98.95 CC 42 (87.50) 44 (93.62) 86 90.53
CA 0 (0.00) 1 (2.13) 1 1.05 CT 6 (12.50) 2 (4.26) 8 8.42
AA 0 (0.00) 0 (0.00) 0 0.00 TT 0 (0.00) 1 (2.13) 1 1.05
48 47 95 48 47 95
C 1.000 0.989 0.995 C 0.938 0.957 0.947
A 0.000 0.315 0.011 0.005 T 0.063 0.043 0.053
n (%) n (%) n (%) n (%) n (%) n (%)
TT 38 (79.17) 40 (85.11) 78 82.11 AA 38 (79.17) 40 (85.11) 78 82.11
TC 10 (20.83) 6 (12.77) 16 16.84 AG 10 (20.83) 6 (12.77) 16 16.84
CC 0 (0.00) 1 (2.13) 1 1.05 GG 0 (0.00) 1 (2.13) 1 1.05
48 47 95 48 47 95
T 0.896 0.915 0.905 A 0.896 0.915 0.905
C 0.104 0.085 0.095 G 0.104 0.085 0.095
p =0.412 p =0.413
p= 0.653 p= 0.653
p =0.495 p =0.268
p= 0.537p= 0.315
p= 0.653p= 0.315
p =0.495 p =0.412
p =0.495 p =1.000
p= 0.667p= 0.315
Position 3027, rs685 Position 3092, rs17244530
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 2868, rs12721036 Position 2994, rs12143180
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 2547, new variant Position 2818, rs12143241
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
Position 2233, rs6413453 Position 2298, rs5088
High HDL Low HDL TOTAL High HDL Low HDL TOTAL
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3.3 LD AND TAGGER ANALYSES OF APOA2 VARIANTS USING HAPLOVIEW 
SNPs that are located close to one another are often inherited together and are compiled 
into haplotypes. “TagSNPs” are a group of SNPs that uniquely identify those haplotypes. 
Identification of TagSNPs using Tagger, helps to reduce the number of common SNPs to be 
screened to gain information. 
3.3.1 American Non-Hispanic Whites 
LD and Tagger analysis (using Haploview) of 18 variants in NHWs (excluding the 
microsatellite) using an r2 cutoff of 0.95 identified 14 bins. Table 15 summarizes the Tagger 
results, and Figure 6 shows the LD plot. As expected, all the rare variants were in individual bins 
and had to be screened individually. 
 
 
Table 15. Tagger Results. The variants that are marked in bold are considered for genotyping the entire 
population. 
 
 
BIN Location of Variants Captured 
rs# of the selected 
variants 
1 2038, 2818, 2994 rs12143180 
2 3027, 3092 rs685 
3 2233, 2868 rs6413453 
4 772 - 
5 2218 - 
6 898 - 
7 336 - 
8 155 rs3829793 
9 3208 rs12721035 
10 3251 - 
11 2085 rs5087 
12 159 - 
13 2115 rs6413452 
14 872 rs5082 
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Figure 7. LD Analysis for NHWs 
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Ten common SNPs (MAF≥5%) were observed in 6 bins. Therefore it would be sufficient 
to screen only 6 variants to gain information on all 10 common variants. TaqMan assays (pre-
made or custom) were available for at least one SNP from 5 out of 6 bins of common SNPs 
(rs12143180, rs6413453, rs3828793, rs5082, 3251). Custom TaqMan design failed for one of the 
common SNP bins. The remaining 8 non-common variants with MAF<5% (that were only 
present in NHWs) were first evaluated for presence of a TaqMan assay (3 were available), 
followed by evaluation by RFLP when TaqMan assay was not available.  
3.3.2 African Blacks 
 LD and Tagger analysis (using Haploview) of 16 variants in Blacks (excluding the 
microsatellite) using an r2 cutoff of 0.95 identified 12 bins. Table 16 summarizes the Tagger 
results, and Figure 7 shows the LD plot. 
 
Table 16. Tagger Results. The variants that are marked in bold are considered for genotyping the entire 
population. 
 
 
BIN Variants Captured 
rs# of the selected 
variants 
1 
2038, 2818, 3027, 
3092 rs685 
2 1638, 2298 rs5088 
3 2868 rs12721036 
4 470 - 
5 2994 rs12143180 
6 589 - 
7 155 rs3829793 
8 2547 - 
9 872 rs5082 
10 1055 - 
11 2233 rs6413453 
12 1569 -  
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Seven common SNPs (MAF≥5%) were presented in 4 bins. Therefore, it would be 
sufficient to screen only 4 variants to gain information about all 7 common variants. TaqMan 
assays (pre-made or custom) were available for at least 3 SNPs from 3 out of 4 bins of common 
SNPs (rs12143180, rs3829793, rs5082). Custom TaqMan design failed for one of the common 
SNP bins. The remaining 9 non-common variants less than 5% MAF (7 of 9 were only present in 
Blacks) were first evaluated for presence of a TaqMan assay (2 were available), followed by 
evaluation by RFLP when TaqMan assay was not available.  
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Figure 8. LD analysis of African Blacks 
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3.4 GENOTYPING SCREENING IN NHWs AND BLACKS 
3.4.1 RFLP 
3.4.1.1 American Non-Hispanic Whites 
Among the 5 rare variants in NHWs, for which there was no available TaqMan assay, 2 
did not affect any restriction site. For 2 of the 3 remaining variants, we were able to successfully 
design RFLP PCR primers (variants at position 336 and 159). 
3.4.1.2 African Blacks 
Among the 6 rare variants in Blacks, for which there was no available TaqMan assay, 2 
did not affect any restriction site. For 2 of the remaining 4 variants, we were able to successfully 
design RFLP PCR primers (variants at positions 1055 and 1569). 
3.4.1.3 NHWs and Blacks 
Our RFLP analysis confirmed the variants at locations 159, 1055, and 1569 by using all 
known heterozygous individuals from 159 and 1569 (N=2 and N=1, respectively) and by using 3 
of 8 known heterozygous individuals from 1055. We failed to confirm the variation identified 
(by sequencing) at location 336 using RFLP. Since the only known heterozygote showed the 
same pattern as the known homozygous wild-types, we concluded that this was not a genuine 
variant, but sequencing noise. The RFLP results are shown in Figure 8, Figure 9, Figure 10 and 
Figure 11. 
 42 
 
 
Figure 9. Variant location 159. 
Gel picture of the Restriction Fragment Length Polymorphism (RFLP) analysis of PCR-amplified DNA samples 
from one wild-type CC homozygous individual and one CG heterozygous individual (as identified by sequencing). 
The PCR fragment has both a polymorphic and non-polymorphic restriction site, so we observe digestion even in 
wild-type homozygotes. CviKI-1 digestion generates two fragments of 129 and 85 base pairs in the CC individual 
and four fragments of 129, 85, 65, and 20 in the CG individual (the smallest 20 bp fragment cannot be visualized 
with our electrophoresis conditions). The third band (65 base pairs) in the CG individual is faint, but can still be 
distinguished.  
 
 
 
Figure 10. Variant location 336. 
Gel picture of the RFLP analysis of PCR-amplified DNA samples from two wild-type TT homozygous individuals 
and two TG heterozygous individuals (as identified by sequencing). The G allele at this location is expected to 
create a restriction site for MspI, therefore the digestion generates only 1 fragment of 200bps in homozygous TT 
individuals vs. 2 fragments of 113bps and 87bps in a heterozygous TG individual. We were not able to observe that 
pattern, and all samples appeared as uncut TT individuals, suggesting that this variant may not be real. 
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Figure 11. Variant location 1055. 
Gel picture of the RFLP analysis of PCR-amplified DNA samples from one CT heterozygous and five wild-type CC 
homozygous individuals (as identified by sequencing.) The C>T variant abolishes a recognition site for enzyme Bsr-
I at location 1055 in APOA2. Restriction endonuclease (BsrI) digestion generates 2 fragments in CC homozygous 
individuals (99bps and 87bps fragments which are not distinguishable at this resolution). In homozygous TT 
individuals, the expected fragment size is 186bp (undigested), and in CT heterozygous individuals, we expect 1 
uncut fragment (186bps) and 2 cut fragments (indistinguishable 99bps and 87bps). 
 
 
 
Figure 12. Variant location 1569. 
Gel picture of the RFLP analysis of PCR-amplified DNA samples from one TC heterozygous and 6 wild-type TT 
homozygous individuals (as identified by sequencing.) The T>C variant creates a recognition site for restriction 
endonuclease MspI at location 1569 in APOA2. MspI digestion generates one fragment of 218 base pairs in a TT 
individual, and three fragments of 218, 128, and 90 base pairs in the TC individual. Expected fragments in a 
homozygous CC individual would be 128 and 90bps. 
3.4.1.4  Pooling Strategy 
To expedite the genotyping process, we employed a pooling strategy, in which 10 
samples were combined after PCR amplification, before RFLP restriction digest. We tried 
pooling 10 samples (one of which carried a known variant) to determine whether we could detect 
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variants on a larger scale. A post-PCR pooling method worked for variants 1055 and 1569, but 
not for 159. Variant 159 was faint in single-sample analysis and could not be detected using the 
pooling method. We will also try 8- and 5-sample post-PCR pooling for 155 and 1569 to 
determine whether we can achieve stronger bands (to decrease the chance for false negatives). 
The following figure (Figure 12) depicts all the variants we identified in APOA2 relative 
to their location in the gene. Variant 336 was not included as we could not confirm it. The color 
FASTA that is used in this figure was obtained from Seattle SNPs Database and revised 
according to the variants identified by sequencing in this study. The variants identified in public 
databases are shown in black font, and the new variants identified in this study are shown in red 
font. The variants that are observed only in one heterozygous individual, and were not confirmed 
by either RFLP or TaqMan are highlighted in yellow, and remain to be confirmed. The 
remaining variants were either observed in more than one individual and/or confirmed with 
RFLP or TaqMan. The minor alleles and their frequencies are depicted on the right (MAF in 
NHWs, MAF in Blacks). When only one frequency is given, the variant was only observed in 
one population. 
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TACGCTCCAG CCTGAGCAAC AAGAGCAAAA CTCTGTCTCA GGAAAACAAA 50            
CAAAAAAACC TGCACATATA CTTCTGAATT TAAAACAAAA GTTAAAAAAC 100            
AAAGATTTCT TGGTCTCTGG TCACTACCTC CCTCATCAGC TTTGCGCCTC 150            
CACTSTCA C CTCAGGAATG TTCCACATAC TCAGCGAGTA TGCTTGGGGG 200 | 155C: 0.321 and 0.063   
GCAAAAGGGT GAAAGATACA AAAGCTTCTG ATATCTATTT AACTGATTTC 250   
ACCCAAATGC TTTGAACCTG GGAATGTACC TCTCCCCCTC CCCCACCCCC 300  
AACAGGAGTG AGACAAGGGC CAGGGCTATT GCCCCTGCTG ACTCAATATT 350  
GGCTAATCAC TGCCTAGAAC TGATAAGGTG ATCAAATGAC CAGGTGCCTT 400  
CAACCTTTAC CCTGGTAGAA GCCTCTTATT CACCTCTTTT CCTGCCAGAG 450  
S , 159G: 0.011 
CCCTCCATTG GGAGGGGACR 470A:0.005
Y 589T :0.021
Y 772T :0.016
 GGCGGAAGCT GTTTTCTGAA TTTGTTTTAC 500 |  
TGGGGGTAGG GTATGTTCAG TGATCAGCAT CCAGGTCATT CTGGGCTCTC 550  
CTGTTTTCTC CCCGTCTCAT TACACATTAA CTCAAAAA G GACAAGATCA 600 |  
TTTACACTTG CCCTCTTACC CGACCCTCAT TCCCCTAACC CCCATAGCCC 650  
TCAACCCTGT CCCTGATTTC AATTCCTTTC TCCTTTCTTC TGCTCCCCAA 700  
TATCTCTCTG CCAAGTTGCA GTAAAGTGGG ATAAGGTTGA GAGATGAGAT 750  
CTACCCATAA TGGAATAAAG A ACCATGAG CTTTCCATGG TATGATGGGT 800 |  
TGATGGTATT CCATGGGTTG ATATGTCAGA GCTTTCCAGA GAAATAACTT 850  
GGAATCCTGC TTCCTGTTGC AYTCAAGTCC AAGGACCTCA GATCTCA AA 900 | 872C:0.405 and 0.195   
GAATGAACCT CAAATATACC TGAAGTGTAC CCCCTTAGCC TCCACTAAGA 950  
GCTGTACCCC CTGCCTCTCA CCCCATCACC ATGAGTCTTC CATGTGCTTG 1000  
TCCTCTCCTC CCCCATTTCT CCAACTTGTT TATCCTCACA TAATCCCTGC 1050  
CCCA TGGGC CCATCCATAG TCCCTGTCAC CTGACAGGGG GTGGGTAAAC 1100 |  
AGACAGGTAT ATAGCCCCTT CCTCTCCAGC CAGGGCAGGC ACAGACACCA 1150 | Exon 1 | UTR  
AGGACAGAGA CGCTGGCTAG GTAAGATAAG GAGGCAAGAT GTGTGAGCAG 1200  
CATCCAAAGA GGCCTGGGCT TCAGTTGTGG AGAGGGAGAG AGCCAGGTTG 1250  
GAATGGGCAG CAGGTAGGGA GATCCCTGGG GAGGAGCTGA AGCCCATTTG 1300  
GCTTCAGTGT CCCCCAAACC CCCACCACCC TCTTCCTAGG CCGCCCTCCC 1350 | Exon 2 | UTR  
CACTGTTACC AACATGAAGC TGCTCGCAGC AACTGTGCTA CTCCTCACCA 1400  
               M  K   L  L  A  A   T  V  L   L  L  T   12 
TCTGCAGCCT TGAAGGTGGG TGTGATATGG AGAGGGGGCC AAAAGGGAGA 1450  
I  C  S  L   E                                         17 
ATGTGCTGGT GGTTATAGCT ACCTATCTGC CTGTGCTCTT ATATCCAGGT 1500  
CTGGCAACCA AAGGGCTCAA AAGGAAGATC ATTCCCTCTC TAAAGCCCAG 1550  
AAAGCCCATC CAAAGATC G GCTGGATACC TTTTTGGGGA GGGGGCAGAG 1600 |  
AGCTGGGGTG GGTACTGGCA GAGGTATGGC AGGAGGC AG GATTCACTGC 1650 |  
TGTGGACCCA GCTGAAAAGA TGTGTGTGT GTGTGTGTGT
R , 898G:0.005
Y  1055T: 0.042
Y  1569C: 0.005
Y  1638T: 0.027
 GTGTGTGTGT G  1  700 | 1671 GT repeat: not evaluated
GT
 
GGGCAGGA GCTTTGGTTC GGAGACAGGC AAAGGAGCCA TGTGTGGAGA 1750 | Exon 3  
        G   A  L  V   R  R  Q  A   K  E  P   C  V  E   31 
GCCTGGTTTC TCAGTACTTC CAGACCGTGA CTGACTATGG CAAGGACCTG 1800  
S  L  V  S   Q  Y  F   Q  T  V   T  D  Y  G   K  D  L  48 
ATGGAGAAGG TCAAGAGCCC AGAGCTTCAG GCCGAGGCCA AGTAAGTCTC 1850  
 M  E  K   V  K  S  P   E  L  Q   A  E  A   K          62 
AGGGCAAGGG GTTCAGGGGC TGTGGAACTG TGGAGAGAAA GAAGGGAAGA 1900  
TGAGAGGTCC CACAGAAGTC TGAACCCAGG GGTGGGGATT AGGGCAGATT 1950  
AGGCTTAAAT TGCAGAGAAA AAGTATTTCA TCACCCAAAG ATCCCACACG 2000  
TCTCTTAGAT AGAGAGGAAC AGCAAGAACT GGGCCTTSAA TTTCAGTCTC 2050 | 2038C :0.083  
TAGAGTCTGT CCCTCTACCT AGCAAAGGTC TTGAYTCTAT TCCTACCTAG 2100 | 2085T: 0.007  
GGGCTTTGCC ATGCRATGGA CCAGGCACTA GAGTTTGGGG ACCTGAGTCA 2150 | 2115A: 0.014  
GTCTGCTCTG ACCTCCCACC ACCACCAAGG CCCCTGCCAG TGCCTAGGGT 2200  
CCCTCAGATT AAACTCT AT CCCCTCACCT ATYCAGGTCT TACTTTGAAA 2250 | 233T: 0.111 | Exon 4  
                                         S   Y  F  E   66 
AGTCAAAGGA GCAGCTGACA CCCCTGATCA AGAAGGCTGG AACGGAA TG 2300 |  
K  S  K  E   Q  L  T   P  L  I   K  K  A  G   T  E  L  83 
GTTAACTTCT TGAGCTATTT CGTGGAACTT GGAACACAGC CTGCCACCCA 2350  
 V  N  F   L  S  Y  F   V  E  L   G  T  Q   P  A  T  Q 100 
GTGAAGTGTC CAGACCATTG TCTTCCAACC CCAGCTGGCC TCTAGAACAC 2400 | UTR  
                                                       100 
CCACTGGCCA GTCCTAGAGC TCCTGTCCCT ACCCACTCTT TGCTACAATA 2450  
AATGCTGAAT GAATCCAGCT CTGAGCCTGG TATGTTTGGG GGACTGGGAA 2500  
M 2218C: 0.005, 2
Y  2298T: 0.026
AAGTAGGGGA GTAAGGGAGG AGAAGAGGAA GGAAAAGGAA AAATCT CTT 2550 |  
CTAGAAGGAG AGAGGTTTGA GTGTGGAGGG GTGAAGAAAG GATTGAAGAC 2600  
ACAACTGATG AAAATGACAG GATGAGGGTG CCATGATTCT CCAAACCCAG 2650  
AGTCTCCTAC AGCCTGGGCA CGACTCTGCA GGTGAACACT AAAGAGGCTT 2700  
TGCATTGCAC AAGGAACTAG GAGAGGAAGG AAGGATTCAC AAACTGAATC 2750  
CCTCGATTTC TGGAGGTCAT AGAAAATGAG GGTACCCTGG TGGGGTGCAG 2800  
TGGCTCACAC CTGTAATYCC TGCACTTTGG GAGGCCAAGG TAGGTGGATC 2850 | 2818T: 0.083  
ACTTGAGATC AGGAGTTMCA GACCAGCCTA GCCAACATGG TAAAACCCCG 2900 | 2868A: 0.111  
TCTCTACTAA AAATACAAAA ATTAGCCAGG TGTTGTGGCA CGTGCCTGTA 2950  
ATCCCAGCTA CTCGGGAGAC TGAGGCATGA GAATCTTTTG AACCGGGGAG 3000 | 2994T: 0.056  
GCGGAGGTTG CAGTGAGCTG ACATCGYGCC ACTGCACTCC AGCCTAGGTG 3050 | 3027C: 0.129  
ACAGAGCAAG ACTCCGTCTC AAAAAAAAAA AAAAAAAAAA ARAAAAGAAA 3100 | 3092G: 0.132  
GTAAAGAAAA AAAGAAAATG AGGGTACCCC TCATAATTTC CTGTTAGTCA 3150  
TTCTATGAAG AAAAGAAAGC TTCCCAAGGT GTCACCCGTG GCCCTCCTTT 3200  
CTTCTRAG CCAGGGGAAC ACTGTGTTTC CCCCTTTCCC ACAATAAAAG 3250 | 3208A: 0.062 
CTTGAGTTT GCTCCTCTCC CTAGAAGTGC TCTAATTTCT CCATTTAAAA 3300 |  
CCTCTTATCT AGACCAGGC 
K  2547T: 0.005
CC
R  3251G: 0.048
Figure 13. APOA2 sequence variants identified in our study 
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3.4.2 TaqMan SNP Genotyping 
We have genotyped 5 variants in Blacks (rs12143180, rs3829793, rs5088, rs6413453, 
rs5082) and 8 variants in NHWs (rs12143180, rs6413453, rs3828793, rs6413452, rs12721035, 
rs5082, rs5087, 3251) using either pre-made or custom-made TaqMan SNP Genotyping Assays. 
Genotyping call rates for a total of 9 assays (4 common to both populations) are shown in Table 
17. The genotyping discrepancy rate was less than 1.5% for each variant based on 10% repeat of 
the samples. 
 
Table 17. Genotyping Call Rates for TaqMan (given in percentages) 
 
Location NHWs Blacks
rs12143180 98.88 96.45
rs3829793 98.88 98.98
rs6413453 99.84 98.48
rs5082 99.2 98.73
rs5088 - 98.73
3251 99.84 -
rs5087 99.52 -
rs6413452 99.84 -
rs12721035 99.84 -  
Comparison of the allele frequencies and genotype distribution of the screened variants 
between NHWs and Blacks is given in Table 18. None of the variants showed any deviation 
from HWE (p>0.05) in each race group. All the variants that were present in both populations 
showed significant differences in genotype and allele frequency when compared between races 
(p<0.0001). 
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Table 18. Genotype and Allele frequencies of APOA2 variants genotyped with TaqMan assays. The 
statistical comparison between NHWs and Blacks was made when the variant was present in both populations. NA= 
not applicable. 
 
APOA2 
variant 
Genotype/Allele  NHWs Blacks APOA2 
variant 
Genotype/Allele NHWs Blacks 
rs6413453 Genotypes n(%) n(%) rs5088 Genotypes n(%) n(%) 
  CC 481(77.21) 765(98.58)  CC - 741(95.49) 
  CT 138(22.15) 11(1.42)  CT - 34(4.12) 
  TT 4(0.64) 0  TT - 3(0.39) 
  total 623 776  total - 776 
  p<0.0001   p=NA 
  Alleles     Alleles    
  C 0.883 0.993  C - 0.973 
  T 0.117 0.007   T - 0.026 
  p<0.0001   p=NA 
 
APOA2 
variant 
Genotype/Allele  NHWs Blacks APOA2 
variant 
Genotype/ 
Allele 
 NHWs Blacks 
rs3829793 Genotypes n(%) n(%) rs12143180 Genotypes n(%) n(%) 
  GG 255(41.32) 650(83.33)  CC 419(67.91) 652(85.79) 
  GC 279(45.21) 123(15.77)  CT 177(28.69) 104(13.68) 
  CC 83(13.45) 7(0.90)  TT 21(3.40) 4(0.53) 
  total 617 780  total 617 760 
  p<0.0001   p<0.0001 
  Alleles     Alleles    
  G 0.639 0.912  C 0.883 0.926 
  C 0.361 0.088   T 0.118 0.074 
  p<0.0001   p<0.0001 
 
APOA2 
variant 
Genotype/Allele  NHWs Blacks APOA2 
variant 
Genotype/Allele  NHWs Blacks 
rs6413452 Genotypes n(%) n(%) rs5087 Genotypes n(%) n(%) 
  GG 609(97.75) -  CC 619(99.68) - 
  GA 14(2.25) -  CT 2(0.32) - 
  AA 0 -  TT 0 - 
  total 623 -  total 621 - 
   p=NA   p=NA 
  Alleles     Alleles    
  G 0.989 -  C 0.998 - 
  A 0.011 -   T 0.002 - 
  p=NA   p=NA 
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 Table 18 Continued
 
APOA2 
variant 
Genotype/Allele NHWs Blacks APOA2 
variant 
Genotype/Allele NHWs Blacks 
rs12721035 Genotypes n(%) n(%) 3251A>G Genotypes n(%) n(%) 
  GG 549(88.12) -  AA 580(93.10) - 
  GA 74(11.88) -  AG 40(6.42) - 
  AA 0 -  GG 3(0.48) - 
  total 623 -  total 623 - 
   p=NA   p=NA 
  Alleles     Alleles    
  G 0.941 -  A 0.963 - 
  A 0.059 -   G 0.037 - 
  p=NA                p=NA 
 
APOA2 
variant 
Genotype/Allele NHWs Blacks 
rs5082 Genotypes n(%) n(%) 
  TT 232 (37.54) 507(65.63)
  TC  297(47.90) 242(30.61)
  CC 90(14.56) 29(3.76) 
  total 618 771 
   p<0.0001 
  Alleles    
  T 0.615 0.809 
  C 0.385 0.191 
  p<0.0001 
 
3.5 LD ANALYSIS USING GENOTYPE DATA FROM ENTIRE POPULATION 
When we repeated LD analysis using data from the entire sample, we observed similar 
LD patterns as were first seen in the smaller sample. Figure 13 and Figure 14 show the D’ and r2 
analysis. 
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3.5.1 Non-Hispanic Whites 
 
Figure 14. D’ and r2 analyses in NHWs 
3.5.2 Blacks 
 
Figure 15. D’ and r2 analyses in Blacks 
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3.6 ASSOCIATION OF APOA2 VARIANTS WITH TOTAL HDL LEVELS 
We analyzed the association of APOA2 variants (genotyped using TaqMan assays) in 
relation to total HDL levels (using square root transformed HDL levels) separately in males and 
females within each ethnic group (Table 19 for NHWs and Table 20 for Blacks). The covariates 
used in NHWs were BMI for males, and BMI, age, and smoking (currently) for females. The 
covariates used in Blacks were waist measurement and carbohydrate intake (as percentage 
calories) for males, and smoking (currently), waist measurement, and minutes of jogging or 
cycling per day for females. 
 
3.6.1 American NHWs 
No significant association was seen in males. In females, we found a significant 
association for 2 variants; 2233C>T/rs6413453 (p=0.028) and 3251A>G (p=0.023). The total 
HDL levels were significantly lower in females who were homozygous for the minor allele for 
each of these variants. Because there were only 3 females who were homozygous for the minor 
alleles of these 2 variants, we repeated our analysis in females by comparing wild-type allele 
homozygotes vs. minor allele heterozygotes+homozygotes. We still observed a slight 
significance for the association of rs6413453 (p=0.043), however there was no longer a 
significant association with 3251A>G (p=0.803). 
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Table 19. Genotype distribution, mean HDL levels, and adjusted p-values for 8 APOA2 variants in NHWs 
 NHW MALES  NHW FEMALES  
rs3829793 GG (127) GC (125) CC (40) GG (127) GC (154) CC (43) 
HDL-C 44.79±11.64 43.69±10.46 43.38±9.20 56.72±14.17 57.23±13.77 54.60±15.81 
 p=0.87a p=0.34b 
rs5082 TT (112) TC(136) CC (45) TT (120) TC (161) CC (44) 
HDL-C 43.62±10.06 44.92±11.85 42.56±9.32 57.25±15.84 57.18±13.73 54.61±13.18 
 p=0.35a p=1.00b 
rs5087 CC (292) CT (2) TT (0) CC (326) CT (0) TT (0) 
HDL-C 44.04±10.85 36.00±9.90 - 56.80±14.45 - - 
 p=0.21a p= NA 
rs6413452 GG (284) GA (11) AA (0) GG (324) GA (3) AA (0) 
HDL-C 43.72±10.73 51.18±11.44 - 56.90±14.50 51.33±3.06 - 
 p=0.08a p=0.92b 
rs6413453 CC (232) CT (61) TT (2) CC (248) CT (77) TT (2) 
HDL-C 44.44± 11.35 42.36± 8.70 42.00±1.41 57.34± 14.54 55.60± 14.01 39.00±5.66 
 p=0.47a p=0.03b 
rs12143180 CC (196) CT (85) TT (11) CC (222) CT (92) TT (10) 
HDL-C 44.17±10.80 43.92±11.46 42.55±7.88 56.95±14.31 57.42±14.92 51.20±13.83 
 p=0.81a p=0.25b 
rs12721035 GG (261) GA (34) AA (0) GG (287) GA (40) AA (0) 
HDL-C 44.01±10.97 43.88±9.86 - 56.76±14.54 57.28±13.84 - 
 p=0.91a p=0.56b 
3251A>G AA (272) AG (20) GG (2) AA (307) AG (20) GG (1) 
HDL-C 43.69± 10.61 48.10± 13.59 40.50±3.54 56.83± 14.31 58.50± 15.09 26.00±NA 
 p=0.18 a p=0.02b 
ap-values for square root-transformed HDL levels, adjusting for “BMI” 
bp-values for  square root-transformed HDL levels, adjusting for “age, smoking status and BMI” 
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3.6.2 African Blacks 
None of the 5 variants showed an association with total HDL levels in males or females 
(Table 20). 
Table 20. Genotype distribution, mean HDL levels, and adjusted p-values for 5 APOA2 variants in Blacks. 
 BLACK MALES  BLACK FEMALES  
rs12143180 CC (402) CT (60) TT (1) CC (236) CT (39) TT (2) 
HDL-C 45.76±12.96 47.58±11.39 56.9±NA 51.01±12.93 53.13±11.30 40.60±14.99 
 P=0.41a p=0.26b 
rs5088 CC (451) CT (19) TT (3) CC (270) CT (14) TT (0) 
HDL-C 46.11±12.80 44.98±10.60 51.13±5.95 51.13±12.56 50.91±14.93 - 
 P=0.47a p=0.98b 
rs3829793 GG (399) GC (72) CC (3) GG (236) GC (46) CC (3) 
HDL-C 45.84±12.96 47.28±11.15 44.03±13.72 50.68±12.78 53.69±11.72 42.70±11.21 
 P=0.53a p=0.16b 
rs6413453 CC (468) CT (3) TT (0) CC (276) CT (8) TT (0) 
HDL-C 46.10±12.72 36.00±2.03 - 51.08±12.65 52.56±13.55 - 
 P=0.22a p=0.90b 
rs5082 TT (316) TC (141) CC (18) TT (179) TC (92) CC (11) 
HDL-C 46.04±12.81 46.27±12.88 45.47±8.55 51.14±12.88 51.35±12.51 51.14±10.93 
 P=1.00a p=0.97b 
ap-values for square root-transformed HDL levels, adjusting for “waist measurement and carbohydrate intake” 
bp-values for square root-transformed HDL levels, adjusting for “smoking, waist measurement, and exercise” 
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4.0  DISCUSSION 
ApoA-II is the second major protein after apoA-I in HDL particles and plays a role in 
HDL metabolism and reverse cholesterol transport. The role of apoA-II in atherogenesis is 
controversial, but it is not a neutral molecule. Studies in mouse models have also produced 
varying results. The APOA2 gene clearly requires further study due to its biological significance 
and lack of consensus in its biological function.  
Our study was aimed to evaluate the APOA2 gene in detail by resequencing DNA 
samples from healthy individuals with extreme levels of HDL (upper and lower 5th percentiles). 
The purpose of using this method was to detect the rare causative variants in addition to common 
variants allowing us to test both the “common variant-common disease” and “rare variant-
common disease” hypotheses.  
Joint analysis of recent genome-wide association studies have identified several genes 
involved in lipid metabolism (Willer et al., 2008 and Kathiresan el al., 2008). Willer et al. (2008) 
confirmed 11 previously implicated loci and identified several new loci by performing meta-
analysis of three genome-wide association studies. Kathiresan et al. (2008) showed that common 
SNPs at 18 loci are reproducibly associated with lipid metabolism including 6 new loci. 
According to both studies, the major loci associated with HDL-cholesterol at genome-wide 
significance level were ABCA1, the APOA1-APOC3-APOA4-APOA5 cluster, CETP, LIPC, 
LIPG, LPL, and GALNT2. While APOA2 is not reported as one of the major loci in these studies, 
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the role of APOA2 in lipid metabolism cannot be dismissed. First of all, several loci with 
significant impact may be overlooked in genome-wide association studies, due to the fact that a 
very low cutoff p-value is often used (P<5 x 10-7). Second, the goal of these genome-wide 
association studies is to identify common SNPs throughout the genome that are associated with 
lipid concentrations, testing the “common variant-common disease” hypothesis, but not being 
able to identify the common variants with small effects or the rare variants. When Willer et al. 
(2008) applied multiple regression models during their meta-analysis; they found that the 
variants identified in their study accounted for only ~5 to 8% of the variation in the lipid traits in 
their population. Because early studies have suggested high heritability rates for lipid traits 
(ranging from 24-83% for HDL), they concluded that additional genetic factors remain to be 
identified, such as common variants with small affects and rare variants. 
Cohen et al. (2004) used a sequencing strategy (coding regions and splice sites) to 
evaluate the rare variants in 3 genes (ABCA1, APOA1, and LCAT) in individuals representing the 
upper and lower 5th percentile of HDL-cholesterol levels in a population-based sample. The 
benefit of selecting individuals with extreme values of quantitative traits is to increase the chance 
of detecting rare variants that may not be present in individuals with commonly observed 
quantitative values. Cohen et al. (2004) concluded that multiple rare nonsynonymous sequence 
variants of the genes that are involved in HDL metabolism may be influencing the HDL-
cholesterol levels (overrepresented in the low-HDL group). Their results supported mainly the 
“rare variant-common disease” hypothesis for the genes that they screened.  
We used a similar approach as Cohen et al. (2004), but we chose to sequence the entire 
gene and flanking regions so that we could also identify the regulatory variants. After sequencing 
95 Black individuals and 95 NHW individuals in the extremes of HDL-cholesterol levels, we 
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found 26 variants (25 single nucleotide changes and 1 microsatellite; the latter was difficult to 
precisely determine using the sequencing strategy). This is more than the 15 variants (14 single 
nucleotide changes and 1 microsatellite) identified by Fullerton et al. (2002) and reported in the 
Seattle database (24 individuals from each of 3 populations; American Blacks, European NHWs, 
and American NHWs). Comparison of the variants identified in both studies is depicted in Table 
21 including allele frequencies.  
Table 21. APOA2 variants and their allele frequencies: Comparison between our study and Seattle SNPs 
Database/Fullerton et al. (2002). The microsatellite marker is not included in this table, but was observed in all 
populations. 
Site Minor allele
JD-pop* ND-pop* RD-pop* NHWs** Blacks**
155 C 0.042 0.250 0.326 0.321 0.063
159 G - - - 0.011 -
201 A - - 0.021 - -
336 G - - - 0.005 -
470 A - - - - 0.005
589 T - - - - 0.021
772 T - - - 0.016 -
872 C 0.333 0.312 0.375 0.405 0.195
898 G - - - 0.005 -
1055 T - - - - 0.042
1218 C - 0.021 - - -
1569 C - - - - 0.005
1638 T - - - - 0.027
2038 C - 0.083 0.167 0.168 0.095
2085 T - 0.021 - 0.005 -
2115 A - 0.021 0.021 0.016 -
2218 C - - - 0.005 -
2233 T 0.021 0.146 0.167 0.084 0.005
2298 T - - - - 0.026
2547 T - - - - 0.005
2818 T - 0.083 0.167 0.168 0.095
2868 A 0.021 0.146 0.167 0.084 0.005
2994 T - 0.021 0.146 0.163 0.053
3027 C - 0.104 0.283 0.200 0.095
3092 G - 0.104 0.292 0.197 0.083
3208 A - 0.062 0.125 0.038 -
3251 G - - - 0.048 -
Minor allele frequency
 
*SeattleSNP Database - JD: Jackson,MS , ND: North_Karelia,Finland, RD: Rochester,MN 
** From our study – NHWs: San Louis Valley, CO, Blacks: Benin City, Nigeria 
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Comparisons of sequencing data and conclusions between our study and their study are 
summarized as follows: 
1. There were 2 variants reported in the Seattle database that were not observed in our 
sequencing sample. Those variants were a G>A variant at position 201 (MAF=0.02, only 
in American NHWs), and a G>C variant at position 1218 (MAF=0.002, only in European 
NHWs). The MAF of these variants suggests that only a single copy of the minor allele 
was observed in the entire white (European and American) population screened. Given 
the fact that our NHW and Black sample size was ~2-4 times larger than their sample 
size, we would expect to observe these variants in our sample. Therefore, we think that 
they may be sequencing artifacts. Alternatively, those variants may be genuine and the 
reason we did not observe them in our population sample could be due to sampling 
difference (subjects chosen in our study on the basis of extreme HDL levels versus 
subjects chosen in their study regardless of health status).  
2. We detected a total of 12 previously unreported variants in our sequencing sample; 6 
were present in NHWs and 6 were present in Blacks. The observation of these new 
variants could be due to a larger sample size allowing us to have a higher detection rate, 
or could be due to their association with extreme HDL levels. Of 7 variants in which only 
a single minor allele in the sequencing sample was observed (4 in NHWs and 3 in 
Blacks), one (2085C>T) was confirmed using TaqMan genotyping of the entire 
population and one (1569T>C) was confirmed using RFLP on selected samples. We 
failed to confirm one variant (336T>G) using RFLP, and considered it to be a sequencing 
artifact. Four variants remain to be confirmed (470G>A, 898A>G, 2218A>C, 2547G>T). 
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3. Previously, Fullerton et al. (2002) observed all population-specific variants as single-
allele copies in their sequencing sample for the APOA2 gene. However, this was not the 
case in our study. All the variants that we observed as only a single allele in NHWs, 
however, were specific to that population. Fullerton et al. (2002) did not detect any 
population-specific variants in American Blacks. We were able to detect a total of 7 
population-specific variants (MAF ranging from 0.005 to 0.042). 
4. Fullerton et al. (2002) found that variant 872T>C had the highest frequency 
(MAF=0.333) among American Blacks, followed by 155G>C (MAF=0.042). We also 
found 872T>C as the most common variant in African Blacks (MAF=0.195). This SNP is 
functional, affecting known transcription binding site in the proximal promoter element 
D. The second most common variants in African Blacks were 2038G>C, 2818C>T, and 
3027T>C (MAF=0.095). Fullerton et al. found 872T>C to be out of HWE in American 
Blacks. The SNP did not show deviation from HWE in African Blacks in our study. 
Given the fact that the MAF of this SNP in American Blacks falls in between what is 
observed in NHWs and African Blacks, deviation from HWE in American Blacks may be 
due to the migration and admixture. 
5. Fullerton et al. (2002) observed a deficit of APOA2 genetic variation in American Blacks 
as compared with American NHWs and European NHWs. They identified a total of 5 
variants in American Blacks versus 15 variants in NHWs both including the 
microsatellite repeat marker. We identified a total of 17 variants in African Blacks versus 
19 variants in NHWs. Even though the number of variants was not low in African Blacks, 
we observed lower rates of heterozygosity. For each single nucleotide variant that was 
common to both NHWs and African Blacks in our study (n=9), African Blacks had 
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significantly lower heterozygosity for rare alleles and lower homozygosity for common 
alleles. All the variants that were present in both populations showed significant 
differences in genotype and allele frequency when compared between races (p<0.0001). 
6. Fullerton et al. (2002) did not observe any variants in the coding region of the gene. 
However, we were able to detect one synonymous sequence variant (2298C>T, 
MAF=0.026) only observed in African Blacks. Because we see no amino acid-changing 
variants, we expect any HDL-associated variants to be regulatory (modulating gene 
expression or affecting RNA processing). Nine of the 15 variants identified by Fullerton 
et al. (2002) did fall in the intronic regions and the remaining 9 (60%) fell in flanking 
regions (3 in 5’-flanking region and 6 in 3’-flanking region). Similarly, we identified 16 
of 25 (64%) variants (excluding the unconfirmed variant at position 336) in the flanking 
regions (8 in 5’-flanking region and 8 in 3’-flanking region). 
7. Fullerton el al. (2002) found that both variants with highest frequency (variants at 
position 155G>C and 872T>C) fell in the 5’-flanking region (putative promoter region). 
We found several variants more frequent than 155G>C, ranging from 5% to 10% 
frequency in the 3’-flanking region, which is different than their observation. 
Cohen et al. (2004) found an increase in rare, nonsynonymous variants for ABCA1, 
APOA1, and LCAT in the low HDL group versus the high HDL group. Of the 128 individuals 
(64 Whites, 64 Blacks) with low plasma levels of HDL-cholesterol, 21 (16%) had unique 
sequence variants (not present in the high HDL-cholesterol group) versus 3 (2%) of individuals 
with unique sequence variants in the high HDL group (not present in the low HDL-cholesterol 
group). They found that the number of synonymous variants was similar in high and low HDL 
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groups. There are no known nonsynonymous changes in APOA2, as confirmed in our study as 
well.  
In NHWs, we found a significant difference of allele frequencies for 2233C>T/rs6413453 
and 2868C>A/rs12721036 SNPs between the high- and low- HDL groups (p=0.038 for each). 
These two SNPs were found to be closely linked to each other in LD analysis. We observed 2 
rare variants (excluding unconfirmed 336T>G) only in the low HDL group (898A>G and 
2085C>T), and 1 rare variant only in the high HDL group (2218A>C). For 6 of 14 SNPs found 
in both groups, homozygosity was observed only in the low HDL group (3251A>G, 2038G>C, 
2233C>T, 2818C>T, 2868C>A, and 2994C>T), although heterozygotes were seen in both high 
and low HDL groups. There was no variant that was observed in homozygosity in only the high 
HDL group. Of the 48 individuals with low plasma levels of HDL, 6 (12.5%) had either rare 
variants (excluding the unconfirmed variant at position 336) not present in the high HDL group 
(N=2) or carried between 1 and 4 variants that were observed in the homozygous state only in 
the low HDL group (N=4). In contrast, of the 47 individuals with high plasma levels of HDL, 
only 1 subject (2.1%) had a rare variant not present in the low HDL group, and none carried 
variants that were homozygous only in the high HDL group. In Blacks, we found no significant 
difference of allele frequencies of APOA2 variants between the high- and low- HDL groups. 
Three rare variants were observed only in the low HDL group (2233C>T, 2547G>T, 2868C>A) 
and 2 rare variants were observed only in the high HDL group (470G>A and 1569T>C). Eleven 
SNPs were present in both high HDL and low HDL groups, but homozygosity was observed 
only in the low HDL group for 6 variants (155G>C, 2038G>C, 2818C>T, 2818C>T, 2994C>T, 
3027T>C, 3092A>G) and observed only in the high HDL group for 1 variant (872T>C). Of the 
47 individuals with low plasma levels of HDL, 4 (8.5%) had either rare variants not present in 
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the high HDL group (N=3) or carried 5 variants that were observed in the homozygous state only 
in the low HDL group (N=1). Of the 48 individuals with high plasma levels of HDL, 3 (6.3%) 
had either a rare variant not present in the low HDL group (N=2), or carried a variant that was 
homozygous only in the high HDL group (N=1). 
This observation of increased number of minor alleles of APOA2 variants (increased 
heterozygosity for rare variants or increased homozygosity for common variants) needs 
confirmation in larger population-based samples. This observation suggests a cumulative effect 
of several regulatory APOA2 variants on plasma HDL concentration. A similar observation was 
made by Cohen et al. (2004) for an accumulation of damaging nonsynonymous alleles of three 
other genes. 
We performed a preliminary analysis using only 9 variants that were screened in NHWs 
(n=624, 8 variants) and/or Blacks (n=788, 5 variants) with TaqMan SNP genotyping assays. No 
association with HDL levels was found in the Black males or females. For the variants that were 
screened in NHWs, we found significant association in only females for variants 
2233C>T/rs6413453 (adjusted p=0.028 for square root transformation of HDL levels) and 
3251A>G (adjusted p=0.023 for square root transformation of HDL levels). However, we were 
not able to confirm the same association in males. Because there were only 3 females who were 
homozygous for the minor alleles of these 2 variants, we repeated our analysis in females by 
comparing wild-type allele homozygotes vs. minor allele heterozygotes+homozygotes. We still 
observed a slight significance for the association of rs6413453 (p=0.043), however there was no 
longer a significant association with 3251A>G (p=0.803). The 2233C>T variant is located at the 
3’ end of intron 3, close to the splice-site junction. The putative promoter variant 
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(872T>C/rs5082/-265T>C) that was found to be associated with other quantitative traits in prior 
studies did not show association with HDL levels in our study.  
Due to time constraints and technical issues (TaqMan assays were not available for all 
variants, therefore more time-consuming methods such as RFLP and pyrosequencing will be 
performed), we were not able to complete genotyping of the remaining variants. When all 
variants are genotyped in the entire population, we will be able to determine the extent to which 
APOA2 variants influence HDL levels in NHWs and Blacks. 
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